Psicología
Permanent URI for this community
Browse
Browsing Psicología by Author "Addington, Jean"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Publication Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis(2024) Wannan, Cassandra M. J.; Nelson, Barnaby; Addington, Jean; Allott, Kelly; Anticevic, Alan; Arango, Celso; Baker, Justin T.; Bearden, Carrie E.; Billah, Tashrif; Bouix, Sylvain; Broome, Matthew R.; Buccilli, Kate; Cadenhead, Kristin S.; Calkins, Monica E.; Cannon, Tyrone D.; Cecci, Guillermo; Chen, Eric Yu Hai; Cho, Kang Ik K; Choi, Jimmy; Clark, Scott R.; Coleman, Michael J.; Conus, Philippe; Cheryl M Corcoran, Cheryl M.; Cornblatt, Barbara; Diaz-Caneja, Covadonga M.; Dwyer, Dominic; Ebdrup, Bjorn H.; Ellman, Lauren M.; Fusar-Poli, Paolo; Galindo, Liliana; Gaspar, Pablo A.; Gerber, Carla; Birkedal Glenthøj, Louise; Glynn, Robert; Harms , Michael; Horton, Leslie E.; Kahn, René S.; Kambeitz-Ilankovic, Joseph; Kane, John M.; Castillo-Passi, RolandoThis article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHRPublication Baseline clinical characterization of participants in the Accelerating Medicines Partnership Schizophrenia Program(2025) Addington, Jean; Liu, Lu; Chu, Monica; Jungert, Karl; Penzel, Nora; Pasternak, Ofer; Farina, Emily; Carrion, Ricardo E.; Corcoran, Cheryl M.; Mittal, Vijay A.; Strauss, Gregory P.; Yung, Alison R.; Alameda, Luis; Arango, Celso; Borders, Owen; Bouix, Sylvain; Breitborde, Nicholas J. K.; Broome, Matthew R.; Cadenhead, Kristin S.; Castillo-Passi, Rolando I.; Chen, Eric Yu Hai; Choi, Jimmy; Coleman, Michael J.; Conus, Philippe; Diaz-Caneja, Covadonga M.; Ellman, Lauren M.; Fusar Poli, Paolo; Gaspar, Pablo A.; Gerber, Carla; Glenthøj, Louise Birkedal; Horton, Leslie E.; Hui, Christy Lai Ming; Kambeitz, Joseph; Kambeitz-Ilankovic, Lana; Kapur, Tina; Kelly, Sinead; Kerr, Melissa J.; Keshavan, Matcheri S.; Kim, Minah; Kim, Sung-WanBackground. This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants. Methods. The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs. Key measures include the Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the Structured Interview for Psychosis-Risk Syndromes, which determined CHR criteria and the severity of attenuated psychotic symptoms (APS). Other measures included the Structured Clinical Interview for DSM-5, scales to assess negative symptoms, depression, suicidal ideation, substance use, social and role functioning, and a selection of patient-reported outcomes. Results. CHR participants presented with more severe ratings on all clinical measures and poorer functioning relative to the CC. There were a few significant small associations between measures of APS and other clinical measures. Conclusion. The results from this study support previous research indicating that CHR individuals face serious clinical challenges beyond the risk of developing psychosis. Findings indicate significant associations among various clinical measures, underscoring the complex nature of the CHR population. Limitations are acknowledged, including the preliminary nature of the data and the need for more in-depth analyses from AMP SCZ papers already in progress. Future work will focus on longitudinal data and further exploration of clinical variables and their relationship with biomarkers.Publication Sample Ascertainment and recruitment sources in the Accelerating Medicines Partnership Schizophrenia Program(2025) Addington, Jean; Shalev, Amy; Liu, Lu; Jahraus, Cari; Chu, Monica; Farina, Emily; Fusar Poli, Paolo; Marcy, Patricia J.; Nunez, Angela R.; Calkins, Monica E.; Alameda, Luis; Arango, Celso; Borders, Owen; Bouix, Sylvain; Breitborde, Nicholas J. K.; Broome, Matthew R.; Cadenhead, Kristin S.; Carrion, Ricardo E.; Castillo-Passi, Rolando I.; Chen, Eric Yu Hai; Choi, Jimmy; Coleman, Michael J.; Conus, Philippe; Corcoran, Cheryl M.; Diaz-Caneja, Covadonga M.; Ellman, Lauren M.; Gaspar, Pablo A.; Gerber, Carla; Glenthøj, Louise Birkedal; Horton, Leslie E.; Hui, Christy Lai Ming; Kambeitz, Joseph; Kambeitz-Ilankovic, Lana; Kapur, Tina; Kelly, Sinead; Kerr, Melissa J.; Keshavan, Matcheri S.; Kim, Minah; Kim, Sung-Wan; Koutsouleris, NikolaosBackground. This paper presents the recruitment sources of clinical high-risk (CHR) and community controls (CC) from the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program, which aims to study various clinical variables and biomarkers in 2040 CHR and 652 CC participants. Methods. A total of 1640 CHR and 514 CC had recruitment source data. The Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the SIPS was utilized to assess CHR criteria and severity of attenuated psychotic symptoms (APSs), and the Global Functioning: Social Scale was used for social functioning. Participants were recruited through various methods, including referrals from healthcare providers, schools, and community agencies, and self-referrals via outreach efforts and advertising. Results. Participants were recruited from 13 different sources, with self-referral being the most common for both CHR and CC. Other notable sources included child and youth services and psychiatric hospitals and departments. Regional differences in recruitment patterns were observed across continents. Differences in age, APS, and social functioning for CHR participants were examined in the top 5 recruitment sources. Overall, self-referred individuals were typically older, with less severe APS and higher levels of functioning, whereas those from adult community mental health services had poorer functioning and more severe APS. The remaining recruitment groups fell between these 2 extremes. Conclusion. This paper highlights the diverse recruitment sources for the AMP SCZ program. Self-referral was a significant source, particularly in North America, reflecting changing help-seeking behaviors influenced by the internet and social media. The findings underscore the importance of understanding recruitment sources to optimize future CHR research.